Lazard Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.05M | Sell |
404,364
-101,774
| -20% | -$515K | ﹤0.01% | 1014 |
|
|
2025
Q1 | $2.68M | Sell |
506,138
-49,712
| -9% | -$263K | ﹤0.01% | 874 |
|
|
2024
Q4 | $3.76M | Sell |
555,850
-86,458
| -13% | -$584K | 0.01% | 708 |
|
|
2024
Q3 | $4.23M | Buy |
642,308
+118,150
| +23% | +$778K | 0.01% | 679 |
|
|
2024
Q2 | $3.93M | Buy |
524,158
+243,490
| +87% | +$1.83M | ﹤0.01% | 738 |
|
|
2024
Q1 | $2.8M | Sell |
280,668
-91,031
| -24% | -$907K | ﹤0.01% | 787 |
|
|
2023
Q4 | $3.66M | Buy |
371,699
+36,675
| +11% | +$362K | ﹤0.01% | 741 |
|
|
2023
Q3 | $2.56M | Sell |
335,024
-10,099
| -3% | -$77.2K | ﹤0.01% | 830 |
|
|
2023
Q2 | $2.58M | Sell |
345,123
-417
| -0.1% | -$3.12K | ﹤0.01% | 843 |
|
|
2023
Q1 | $2.3M | Buy |
345,540
+181,631
| +111% | +$1.21M | ﹤0.01% | 891 |
|
|
2022
Q4 | $1.26M | Sell |
163,909
-140,303
| -46% | -$1.08M | ﹤0.01% | 976 |
|
|
2022
Q3 | $3.24M | Buy |
304,212
+14,603
| +5% | +$155K | ﹤0.01% | 793 |
|
|
2022
Q2 | $2.36M | Buy |
289,609
+100,685
| +53% | +$819K | ﹤0.01% | 870 |
|
|
2022
Q1 | $1.35M | Buy |
188,924
+45,540
| +32% | +$326K | ﹤0.01% | 959 |
|
|
2021
Q4 | $2.46M | Buy |
+143,384
| New | +$2.46M | ﹤0.01% | 898 |
|